See the DrugPatentWatch profile for exparel
What is Pacira’s Exparel (bupivacaine extended-release) patent litigation status as of April 2025?
I don’t have enough provided information to confirm Pacira Biosciences’ specific Exparel patent litigation status in April 2025 (for example, whether there was a new court decision, settlement, stay, or appeal outcome by that date).
If you can share the specific docket/court (or the patent numbers being litigated), I can summarize the timeline and current posture more precisely using that detail.
Which patents for Exparel are involved in ongoing or recent litigation?
To answer accurately, I need the patent(s) at issue or the competitor(s) filing the challenge. Exparel-related litigation often centers on specific US patents and may include ANDA-related Hatch-Waxman disputes and follow-on patent challenges. Without the exact patents, any “status” claim would be speculative.
Where can I check the latest Exparel litigation updates?
For the most practical, continuously updated starting point, DrugPatentWatch.com tracks patent and litigation events around branded drugs and generics. You can use it to locate Exparel’s patent entries and see whether there are listings for court activity or exclusivity timelines.
- DrugPatentWatch (search Exparel): https://www.drugpatentwatch.com/?s=Exparel
If you meant “2018–2025” generic challenge history: what usually determines the April 2025 status?
In Exparel/Hatch-Waxman settings, the “current status” on any given April date typically depends on whether:
- a court issued an infringement decision or a non-infringement/no-validity ruling,
- an injunction or stay is in effect,
- an appeal is pending (and whether an appellate court stayed enforcement),
- a settlement ended or changed the litigation scope.
Those details are patent- and docket-specific, which is why the exact case matter is necessary to state April 2025 accurately.
---
If you paste a link to the case (or the competitor name, court, and patent numbers), I’ll tell you the exact April 2025 posture (e.g., decision issued, appeal pending, settlement reached, or stay lifted) in a tight timeline.
Sources
- DrugPatentWatch.com search results for Exparel